Home › Langerhans-Cell Histiocytosis › California
Langerhans-Cell Histiocytosis clinical trials in California
3 studies for Langerhans-Cell Histiocytosis are looking for participants at sites in California.
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
- Kaiser Permanente Downey Medical Center, Downey
- Loma Linda University Medical Center, Loma Linda
- Miller Children's and Women's Hospital Long Beach, Long Beach
- and 6 more
RecruitingPhase 2
180 Days – 22 Years · All sexes · Updated Oct 2, 2026 · NCT05828069Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
- Children's Hospital of Orange County, Orange
- UCSF Benioff Children's Hospital, San Francisco
RecruitingPhase 2
All ages · All sexes · Updated Sep 18, 2025 · NCT04079179Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- Stanford Children's Hospital, Lucile Packard Children's Hospital, Palo Alto
- Rady Children's Hospital - San Diego, San Diego
RecruitingPhase 3
Up to age 21 · All sexes · Updated Sep 11, 2025 · NCT02670707From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.